Related Experiment Video
Updated: Jun 29, 2025

10:27
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
7.2K
Targeting the Warburg Effect in Cancer: Where Do We Stand?
Ignasi Barba1,2, Laura Carrillo-Bosch2, Joan Seoane2,3
1Faculty of Medicine, University of Vic-Central University of Catalonia, 08500 Vic, Catalonia, Spain.
International Journal of Molecular Sciences
|March 28, 2024
Summary
The Warburg effect, a cancer cell metabolism shift, fuels tumor growth and immune evasion. Targeting this metabolic hallmark offers potential for novel cancer therapies and early diagnostics.
Area of Science:
- Oncology
- Cancer Metabolism
- Immunology
Background:
- The Warburg effect, increased glycolysis even with oxygen, is a key cancer hallmark.
- Elevated lactate and acidity in the tumor microenvironment (TME) impact immune cells and promote tumor progression.
- The Warburg effect drives tumor progression and immunosuppression via multiple mechanisms.
Purpose of the Study:
- To review the current understanding of the Warburg effect in cancer.
- To summarize therapeutic strategies targeting glycolytic enzymes and discuss challenges.
- To examine the Warburg effect's utility in early cancer diagnostics and its role in the TME.
Main Methods:
- Literature review of the Warburg effect in cancer.
- Summary of pharmacological strategies targeting glycolytic enzymes.
- Analysis of lactate's role in the tumor microenvironment and anti-tumor immunity.
Main Results:
- The Warburg effect promotes tumor progression and immunosuppression.
- Targeting glycolytic enzymes faces challenges in therapeutic efficacy.
- Lactate in the TME plays multifaceted roles, influencing tumor-immune cell interactions.
Conclusions:
- The Warburg effect is a critical factor in cancer progression and immune evasion.
- Targeting cancer metabolism presents therapeutic opportunities and challenges.
- Lactate modulation in the TME could enhance anti-tumor immunity.
More Related Videos
Related Concept Videos
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
M-Cdk Drives Transition Into Mitosis
5.6K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.6K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Tumor Progression
6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K

